Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 13,176 shares, a decrease of 63.4% from the January 15th total of 35,983 shares. Based on an average daily volume of 89,790 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 89,790 shares, the days-to-cover ratio is presently 0.1 days.

Fresenius SE & Co. Stock Performance

OTCMKTS FSNUY opened at $14.92 on Wednesday. The firm has a market cap of $33.61 billion, a P/E ratio of 27.13 and a beta of 0.75. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Fresenius SE & Co. has a 52-week low of $9.54 and a 52-week high of $33.93. The business’s 50-day moving average price is $14.29 and its 200 day moving average price is $14.18.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research report on Monday, October 27th. Finally, Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.